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Handling Executive Committee member: Prof. David Gray 
 
Please note that the correspondence below does not include the standard editorial instructions regarding 
preparation and submission of revised manuscripts, only the scientific revisions requested and addressed.  
 
 
First Editorial Decision – 8 April 2014 
 
Dear Prof. Li,  
 
Manuscript ID eji.201444625 entitled "Antitumor effector B cells directly kill tumor cells via Fas/FasL and 
CXCL12/CXCR4 pathways and are regulated by IL-10" which you submitted to the European Journal of 
Immunology has been reviewed. The comments of the referees are included at the bottom of this letter. 
  
A revised version of your manuscript that takes into account the comments of the referees will be 
reconsidered for publication. 
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You should also pay close attention to the editorial comments included below. **In particular, please edit 
your figure legends to follow Journal standards as outlined in the editorial comments. Failure to do this will 
result in delays in the re-review process.** 
  
Please note that submitting a revision of your manuscript does not guarantee eventual acceptance, and 
that your revision will be re-reviewed by the referees before a decision is rendered. 
  
If the revision of the paper is expected to take more than three months, please inform the editorial office. 
Revisions taking longer than six months may be assessed by new referee(s) to ensure the relevance and 
timeliness of the data. 
  
Once again, thank you for submitting your manuscript to European Journal of Immunology and we look 
forward to receiving your revision. 
  
Yours sincerely,  
Laura Soto Vazquez  
 
On behalf of Prof. David Gray  
 
Editorial Office  
European Journal of Immunology  
e-mail: ejied@wiley.com  
www.eji-journal.eu  
 
*************************************************  
 
Reviewer: 1  
 
Comments to the Author  
 
Tao et al examine the role of effector B cells in the cytotoxic elimination of tumor cells. The authors show 
that B cells isolated from tumor draining lymph nodes secrete IL-10, reduce metastases on adoptive 
transfer and have cytotoxic activity in vitro. Cytotoxic activity is repressed by IL-10 and dependent on 
FasL. Through an undefined mechanism, antagonizing CXCR4 signaling represses cytotoxicity. Overall, 
the experiments are clear, but there are a number of gaps in connecting various portions of the report. 
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1. Although the B cells display a convincing cytotoxic activity, it is still much less than the activity of T cells 
(Fig. 4). Are T cells required for the B cell anti-tumor activity? This would be important to show if the B 
cells are acting directly, as suggested by this report, or indirectly by inducing T cell activity. 
  
2. Can the authors show by FACS analysis that B cells are FasL+? If IL-10+ B cells are purified, is FasL 
expression enriched? 
  
3. The link between the B cell/IL-10/FasL story and the AMD3100/CXCR4 story is not very clear. Are the 
CD19+IL-10+ cells also CXCR4+, or is the CXCR4+ population distinct? Moreover, it is not clear how 
AMD3100 would affect cytotoxicity since migration in a killing assay should not be a factor. Perhaps the 
AMD3100/CXCR4 data could be moved to a separate report after it is developed further. 
  
4. There are two pieces of data suggesting this system is not entirely physiological. First, a large number 
of B cells needs to be transferred to see the effect. It might help to know how many of the transferred B 
cells still survive when metastases are examined. Second, anti-IL-10 does not have any effect when 
administered without B cells. This would at least suggest that the proposed mechanism is not operating in 
endogenous B cells during normal tumor immunity. These points should be discussed further by the 
authors. 
  
 
Reviewer: 2  
 
Comments to the Author  
I have reviewed the manuscript by Tao et al. The manuscript combines two different observations that 
apply to tumor-draining LN B cells: 1. A suppressory role of IL-10 producing B cells and 2. Cytotoxic killing 
of tumor cells by TD-LN B cells. They demonstrate that killing activity is suppressed by IL-10 production. 
The findings are well described and technically sound. Demonstration of in vivo effects merits attention 
albeit the results of the study overall are not surprising. 
  
Major criticisms:  
Fig. 1: In Fig. 1A we see a specific subset producing IL10. What are the frequencies of IL-10 producing 
cells in normal LN? Are these B cells increased in TD-LN? in Fig. 1C we see an overall shift (increase in 
MFI, not percentage of cells) that produce Il-10. This should be described and commented. 
 Where are these cells located (histology)?  
Why did the authors look for CD25 expression?  
Can the “Killer”-B cells be distinguished from the IL-10 producing B cells?  
Clarify why IL-2 was injected. How does the absence of IL-2 influence the result? 
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 Is a 95% purity sufficient to judge on the effects? Could the IL-10 act on contaminating DC or T cells? 
What is the cellular composition of the TN-LD cell suspensions w/o B cells? 
 Please, show gating strategies and results of B cell purity.  
Fig. 2: Why is the effect of IL10 depletion only seen when low cell numbers are used for transfer? Are 
there contaminating cells that produce IL-10? If not, then why is the result achieved with anti-IL10 better? 
 Did the authors check for differences in leukocyte subpopulations in TD-LN of IL10 Ko versus WT mice? 
Do cell numbers injected need to be adjusted? Do they represent a bias? 
 Did the authors check for Fas and CXCL12 expression in T cells of TD-L of WT versus IL-10 KO mice? 
  
Open questions:  
Does the IL-10 produced by B cells act in an antigen-dependent manner? Please, discuss. 
  
Minor details  
Check phrase “immunofluorescence assay” on page 13.  
Fig. 4: symbols are hard to distinguish in black and white  
Material and methods:  
Please, specifiy source and include citations for  
- IL-10 KO mice and transgene used  
- Cell lines: 4T1, Renca, TSA  
- FGK45 mAb ascites 
 
 
 First revision – authors’ response – 30 October 2014 
 
 Reviewer: 1 
   
1. Although the B cells display a convincing cytotoxic activity, it is still much less than the activity 
of T cells (Fig. 4). Are T cells required for the B cell anti-tumor activity? This would be important to 
show if the B cells are acting directly, as suggested by this report, or indirectly by inducing T cell 
activity. 
 
T cells are not required for B cell anti-tumor reactivity in vivo.  In our previous report (JI 2009 Ref 7) we 
demonstrated that the adoptive transfer of purified effector B cells were highly effective in mediating tumor 
regression of established subcutaneous tumors in hosts that had been preconditioned with total body 
irradiation (500 cGy) which eliminated host T cells.  This clearly indicates that B cells can act directly in 
causing tumor destruction in vivo.  We have added this point in the Discussion.  The reviewer is also 
correct that adoptively transferred effector B cells can also induce host T cell activity which was reported 
in a subsequent study that we published in Clin Cancer Res 2011 (Ref 8).  
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2. Can the authors show by FACS analysis that B cells are FasL+? If IL-10+ B cells are purified, is 
FasL expression enriched? 
 
We appreciate these constructive comments, and examined the expression of FasL on B cells by FACS 
analysis. Because of technical difficulties to purify IL-10
+
 B cells, we alternatively used TDLN B cells 
isolated from IL-10
-/-
 knockout mice and compared their FasL expression with WT TDLN B cells.  
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As shown in Fig. 5B (new), approximately 5% of the purified and anti-CD40/LPS activated/expanded 
(A/E) WT TDLN B cells expressed FasL.  These are the effector cells we used for adoptive transfer; in 
vitro killing assays, and anti-FasL blockade 
throughout the study. As also observed in 
Fig. 5B (new), there is a similar percentage 
(~8%) of the IL-10
-/-
 TDLN B cells expressing 
FasL, showing no significant difference 
between these two types of B cells.  
Interestingly, we found that when these 
purified and activated/expanded 4T1 TDLN B 
cells were co-cultured in vitro with 4T1 tumor 
cells, the FasL expression was increased on 
the B cells. As revealed on Fig. 5B (new), 
after the effector WT TDLN B cells were 
cultured with the target 4T1 cells at the ratio 
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of 3:1 and 10:1 for 24 hours, the FasL expression on the B cells increased from 5.1% to 13.5% and 18.0% 
respectively.  We observed similar increase of FasL expression on the IL-10
-/- 
TBLN B cells after their co-
culturing with 4T1 tumor cells in Fig. 5B (new). It is of note that data from Figs 2A and B respectively 
revealed that IL-10
-/-
 B cells are more potent antitumor effector cells than WT B cells (at low doses) both in 
vivo and in vitro.  This would suggest that B cell-mediated antitumor immunity involves other signaling 
pathways in addition to Fas/FasL.  For this, we have added two more references in this revision (new refs 
#27 and #34).  
 
Furthermore, we detected Fas expression in target 4T1 tumor cells, and found that in 3 of the 3 
experiments performed,  a very high percentage (~100%)  of the 4T1 tumor cells expressed Fas (new Fig. 
5C).  4T1 expression of Fas provides a target for activated TDLN B cells to induce cell death through the 
Fas/FasL pathway. We have added this in the Materials and Methods, Results, Discussion, and Figure 
Legends sections.  
 
 
3. The link between the B cell/IL-10/FasL story and the AMD3100/CXCR4 story is not very clear. Are 
the CD19+IL-10+ cells also CXCR4+, or is the CXCR4+ population distinct? Moreover, it is not clear 
how AMD3100 would affect cytotoxicity since migration in a killing assay should not be a factor. 
Perhaps the AMD3100/CXCR4 data could be moved to a separate report after it is developed 
further. 
 
We agree with this suggestion of the reviewer, and deleted the AMD3100/CXCR4 data (original Figs. 5B, 
C and D) in this revision.  
 
  
4. There are two pieces of data suggesting this system is not entirely physiological. First, a large 
number of B cells needs to be transferred to see the effect. It might help to know how many of the 
transferred B cells still survive when metastases are examined. Second, anti-IL-10 does not have 
any effect when administered without B cells. This would at least suggest that the proposed 
mechanism is not operating 
in endogenous B cells during 
normal tumor immunity. 
These points should be 
discussed further by the 
authors. 
 
Thank you for these 
constructive comments.  To 
address the first concern 
regarding how many of the 
transferred B cells still survive 
when metastases are 
examined, we conducted an 
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extensive series of additional experiments.  In these new experiments, before adoptive transfer, we 
labeled the activated/expanded TDLN B cells with 10 μM Cell Tracker™ Orange CMTMR (5-(and-6)-(((4-
chloromethyl) benzoyl) amino) tetramethyl rhodamine) (Life Technology, Grand Island, NY ) at 37°C for 45 
minutes in the dark.   When observed under flurorescence microscopy, all the B cells were labeled 
successfully (new Fig. 6A, B). After adoptive transfer, spleens, TDLNs, lungs and primary tumors were 
harvested at different time 
points to detect the labeled live 
B cells in these tissues by flow 
cytometry. New Fig. 6C shows 
the percentage of the labeled 
and adoptively transferred B 
cells among the total CD19
+
 B 
cells detected in different 
tissues on different days; 
including day 14 after B cell 
transfer when metastases were 
examined. The results show 
that low percentage of 
transferred TDLN B cells were 
found in the spleen and TDLNs. 
However, high percentage of 
transferred B cells was found 
alive in the lungs and in the 
primary tumor.  These data are 
associated with the observed 
inhibition of lung metastases 
from the primary tumor after B 
cell adoptive transfer in this 
study (Fig 2A, 3, and new Fig 
7A). 
 
 
 
In addition, New Table 1 shows the absolute number of the labeled and adoptively transferred B cells 
detected in different tissues on different days as indicated.  Clearly, larger numbers of the transferred B 
cells were found in the spleen and TDLN from day 1 to day 14 after B cell adoptive transfer. 
Tab. 1:  Numbers of transferred B cells detected in tumor-bearing BALB/c mice on days  
after B cell adoptive transfer as indicated (Mean ± SE) 
 Primary tumor 
(× 10
4
) 
Lung 
(× 10
4
) 
Spleen 
(× 10
4
) 
TDLN 
 (× 10
4
) 
1 day 3.67 ± 0.38  1.97 ± 0.34  7.44 ± 0.97  5.33 ± 1.04
a
 
5 days 14.23 ± 1.39 5.87 ± 0.77 24.15 ± 5.24 35.90 ± 2.33
b
 
9 days 17.34 ± 0.58 13.41 ± 0.95 43.34 ± 4.34 28.37 ± 3.03
c
 
14 days 16.18 ± 2.16 14.71 ± 1.91 42.06 ± 9.55 26.87 ± 5.56 
a 
p<0.05, TDLN vs. Lung. 
b
 p<0.05, TDLN vs. Primary tumor or vs. Lung. 
                                   c
 p<0.05, TDLN vs. Primary tumor or vs. Lung or vs. Spleen. 
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In the above experiments (new Fig 6C),  we  also 
used normal mice transferred with the similarly 
labeled TDLN B cells, and found  very few  
transferred B cells in the lung  of the normal mice 
(new Fig. 6D) as well as in the spleen and in the 
LN of the normal mice (data not shown).   These 
results imply that the adoptively transferred B cells 
traffic to the tumor and the metastasis sites in 
vivo. Data are representative of two experiments 
performed.  We have added these in the Materials 
and Methods, Results, Discussion, and Figure 
Legend sections. 
 
           
 
For the second concern, anti-IL-10 does not 
have any effect when administered without B 
cells. This would at least suggest that the proposed mechanism is not operating in endogenous B 
cells during normal tumor immunity. These points should be discussed further by the authors. 
 
In addressing the second point, that anti-IL-10 mAb does not impact on endogenous B cells is correct in 
this setting.  We have previously reported (Journal of Immunology, 1997, 159: 664-673----we have added 
this reference in this revision as new ref #32) that in the 3-day established pulmonary metastatic model 
the iv administration of neutralizing IL-10 mAb does not impact on the number of pulmonary metastases 
compared to untreated mice.  This would indicate that the endogenous T and B cell host responses are 
not sufficiently activated to mediate tumor regression when IL-10 is neutralized.  In that same study, we 
found that adoptive transfer of activated T cells mediated tumor regression that was enhanced by IL-10 
neutralization.  This latter study plus our current data indicate that the adoptive transfer of either T or B 
effector cells are necessary to see an effect of IL-10 neutralization. 
 
 
Reviewer: 2 
  
Major criticisms: 
1. In Fig. 1A we see a specific subset producing IL10. What are the frequencies of IL-10 
producing cells in normal LN? Are these B cells increased in TD-LN?  
 
To answer this question, we performed additional experiments, and summarized the data in new Fig. 1. 
E-H. There are almost no IL-10 producing B cells in normal LN (<1% before A/E, new Fig. 1E; <2% post 
A/E, new Fig. 1G).  However, these IL-10
+
 B cells are significantly increased in TDLNs (~3% before A/E, 
new Fig. 1F; ~10% post A/E, new Fig. 1H).  Data are representative of two experiments performed. We 
have added this in the Materials and Methods, Results, Discussion, and Figure Legend sections.  
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2.  In Fig. 1C we see an overall shift (increase in MFI, not percentage of cells) that produce Il-10. 
This should be described and commented. 
 
We adopted this suggestion and measured the MFIs. Based on the original data in Fig. 1C, the MFI of 
sample IL-10 is 95 which is higher than the isotope control MFI (14). Similarly, the MFI of sample CD19 is 
544 which is obviously higher than isotope control MFI (13).  
 
  
3. Where are these cells located (histology)?  
 
This is a very important issue, and was also raised by Reviewer #1. Please see our responses to Item 4 
of Reviewer 1 above.  
 
 
4. Why did the authors look for CD25 expression? 
 
This question is related to question 6 raised by this same reviewer. Please see our responses below to 
question 6. 
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5. Can the “Killer”-B cells be distinguished from the IL-10 producing B cells? 
 
We performed extensive flow cytometry on the TDLN B cells to determine their surface phenotypes and 
whether co-expression of FasL and IL-10 was apparent. The surface marker expression of the TDLN B 
cells was very uniform before and after A/E in that almost all B cells (>98%) were of a classical follicular B 
cell phenotype (IgM
low
CD23
+
CD21
low
CD5
neg
CD1d
low
). This is very different than previously described 
phenotypes of mouse killer B cells (IgM
high
CD5
+
)(Ref 35) or the major IL-10 producing regulatory B cell 
subsets (CD5
+
CD1d
high
 B10 cells)(Ref 24) or (CD21
high
CD23
high
 T2-MZP cells)(Ref 30). We conclude that 
the TDLN B cells have atypical killer or IL-10 producing regulatory B cells.  
 
Similar to what has previously been shown (Ref 35); the co-staining of IL-10 and FasL could not be 
demonstrated in TDLN B cells in this study. This is a technical difficulty because the stimulation required 
to induce IL-10 protein levels measurable by intracellular staining simultaneously results in the loss of 
FasL expression. From the previous study, it was also demonstrated that sorted FasL
+
 B cells were no 
better or worse at producing IL-10 than FasL
neg
 B cells, suggesting that the two molecules do not 
necessarily come from the same B cell.  
 
6.  Clarify why IL-2 was injected. How does the absence of IL-2 influence the result? 
 
This is a very interesting question. While IL-2 was originally produced as a “T cell growth factor”, we have 
found that it can significantly enhance the antitumor immunity of our B effector cells in adoptive therapy. 
To investigate the role of IL-2 in adoptive immunotherapy of cancer using effector B cells, we compared 
the therapeutic efficacy of adoptively transferred WT TDLN B cells with vs. without IL-2 administration.  
Two weeks after 4T1 tumor cells were injected into the mammary fat pad; tumor-bearing WT BALB/c mice 
were treated with activated TDLN B cells or TDLN B cells plus IL-2 respectively.  Another two weeks later, 
mice lungs were collected to enumerate pulmonary metastases. As shown in new Fig 7A Expt. 1, a 
suboptimal does of WT 4T1 TDLN B cells alone showed no efficacy, but adoptively transferred B cells with 
IL-2 administration i.p. significantly inhibited the metastasis of 4T1 tumor cells from the injection site 
(mammary fat pad) to the lung.  However, IL-2 alone resulted in no significant reduction in pulmonary 
metastases compared with PBS-treated controls (new Fig 7A Expt. 2).  This indicated that exogenous IL-
2 administration enhanced 
the antitumor reactivity of 
adoptively transferred effector 
B cells. 
To understand if the IL-2 is 
acting upon B cell directly or 
indirectly, we tested IL-2R 
(CD25) expression on 4T1 
TDLN B cells. Figs. 7B and 
C (was Fig. 1E and F) show 
that expression of IL-2R on 
freshly purified TDLN B cells 
from WT and IL-10
-/- 
mice 
was similar (about 10%). Post 
activation and expansion in 
vitro, expression of IL-2R 
were increased both on WT 
and IL-10
-/-
 TDLN B cells to a 
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similar level (16-18%) (Fig.7D, E, was Fig.1G, H).  These results suggest that IL-2 may act on TDLN B 
cells directly.  Data are representative of two experiments performed. We have added these in the 
Materials and Methods, Results, Discussion, and Figure Legend sections. 
 
 
7.  Is a 95% purity sufficient to judge on the effects? Could the IL-10 act on contaminating DC or T 
cells? What is the cellular composition of the TN-LD cell suspensions w/o B cells? 
 
Using the same protocol to generate effector B cells from 4T1 TDLN, we reported a 98% purity of B cells 
after activation with LPS/anti-CD40 in a previous report (CCR 2011 Ref 8) as well as in this study (Fig. 1).  
We do not feel that any contaminating cells within the remaining 2% of cells could contribute to the 
enhancing effect of the IL-10 neutralization.  This would assume that LPS/anti-CD40 culture of 
contaminating DC or T cells (at 2% of the infused cells) would have an antitumor effect.  We are unaware 
if such activated DC or T cells mediate antitumor reactivity in adoptive therapy. 
 
 
8. Please, show gating strategies and results of B cell purity. 
 
B cells were stained with anti-CD19, and an aliquot of 10,000 cells was analyzed using flow cytometry. 
Cells were initially gated on forward and side scatter to remove debris and calculated by quadrant dot plot.  
With this gating strategy, B cell purity is higher than 95% consistently. This shows that the method we 
used to isolate TDLN B cells is effective. We have added this in the  
Materials and Methods and Figure 1 & 5 Legends.  An example of the flow analysis has been previously 
reported by us (CCR 2011 Ref 8). 
 
9. Fig. 2: Why is the effect of IL10 depletion only seen when low cell numbers are used for 
transfer? Are there contaminating cells that produce IL-10? If not, then why is the result achieved 
with anti-IL10 better?  
 
The effect of IL-10 deletion was seen in the group that received lower numbers of B cells, because that 
dose of cells in the WT group was sub-therapeutic, thus allowing us to detect an improvement with the B 
cells obtained from the IL-10
-/- 
knockout  mice.  At the higher dose of cells, we were observing a maximal 
therapeutic effect; hence, the deletion of IL-10 was not expected to show a significant enhancing effect. 
 
10. Did the authors check for differences in leukocyte subpopulations in TD-LN of IL10 Ko versus 
WT mice? Do cell numbers injected need to be adjusted? Do they represent a bias? 
 
We did not check the differences in leukocyte subpopulations between WT vs. IL-10
-/- 
knockout mice.  The 
B cells used for all experiments were purified from the TDLN of these two groups and subsequently 
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activated.  As illustrated in Fig 1 A-D, the percentages of CD19 B cells before and after activation 
approximated 100% for both groups.  We do not believe any adjustment needed to be made between the 
two groups when it came to in vitro and in vivo experiments. 
 
11. Did the authors check for Fas expression in T cells of TD-L of WT versus IL-10 KO mice? 
 
In this revision, we checked Fas expression on WT and IL-10
-/-
 TDLN T cells.  Before A/E, about 70% T 
cells are Fas
+ 
(WT and IL-10
-/-
 TDLN T cells are similar).  Post A/E, Fas
+ 
TDLN T cells increased and 
nearly all of the T cells are Fas
+
 (both WT and IL-10
-/-
 TDLN T cells).  Considering our focus in this study 
on the integration of antitumor effector B cells with target tumor cells, we did not include this data in the 
revision of this manuscript.  
 
Open questions: 
Does the IL-10 produced by B cells act in an antigen-dependent manner? Please, discuss. 
We did not examine this question in any experimental manner.  
 
Minor details 
Check phrase “immunofluorescence assay” on page 13. 
We have used the term “flow cytometry” in this revision. 
 
Fig. 4: symbols are hard to distinguish in black and white Material and methods: 
Please, specifiy source and include citations for 
-        IL-10 KO mice and transgene used 
IL-10 KO (IL-10
-/-
) mice on BALB/c background are homozygous for a targeted mutation in the IL-10 gene. 
The Il10
tm1Cgn
 mutation was achieved by a targeting vector designed to replace codons 5-55 of exon 1 of 
the targeted gene with a 24 bp linker (providing a termination codon) and a neo expression cassette, as 
well as introduce a termination codon into exon 3. IL-10 KO (IL-10
-/-
) mice were purchased from the 
Jackson Laboratories, Bar Harbor, ME. We have added this to Materials and Methods. 
 
-       Cell lines: 4T1, Renca, TSA 
4T1 is a mammary carcinoma syngeneic to Balb/c mice (provided by Dr. M. Sabel, University of 
Michigan). Renca is a kidney cancer cell line and TSA a highly aggressive mammary adenocarcinoma, 
and these cell lines are all syngeneic to Balb/c mice and used as specific controls. Renca and TSA are 
purchased from ATCC (American Type Culture Collection, Rockville, MD). We have added this to 
Materials and Methods. 
 
-       FGK45 mAb ascites 
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FGK45 mAb ascites were generated using FGK45 hybridoma cells by the Hybridoma Core at the 
University of Michigan. FGK45 hybridoma cells are purchased from ATCC. We have added this to 
Materials and Methods. 
 
 
Second Editorial Decision – 13 November 2014  
 
Dear Prof. Li,  
 
Thank you for submitting your revised manuscript ID eji.201444625.R1 entitled "Antitumor effector B cells 
directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10 and IL-2" to the European 
Journal of Immunology. Your manuscript has been re-reviewed and the comments of the referee(s) are 
included at the bottom of this letter. 
  
Although the referee(s) have recommended publication, some revisions to your manuscript have been 
requested. Therefore, I invite you to respond to the comments of the referee(s) and revise your manuscript 
accordingly. 
  
You will see that reviewer 2 feels that despite the wealth of data provided the paper leads to more 
questions than answers. We feel that clarifying all these questions would expand your manuscript 
unnecessarily, since sience always opens up new questions. So we ask you to comment on each of the 
reviewers concerns and re open questions of mechanism in your discussion. The concerns are highlighted 
in the attached text file. 
  
You should also pay close attention to the editorial comments included below.  
**In particular, please edit your figure legends to follow Journal standards as outlined in the editorial 
comments. Failure to do this will result in delays in the re-review process.** 
  
 
If the revision of the paper is expected to take more than three months, please inform the editorial office. 
Revisions taking longer than six months may be assessed by new referee(s) to ensure the relevance and 
timeliness of the data. 
  
Once again, thank you for submitting your manuscript to European Journal of Immunology. We look 
forward to receiving your revision. 
  
Yours sincerely,  
Karen Chu  
Peer review correspondence 
on behalf of Prof. David Gray  
 
Dr. Karen Chu  
Editorial Office  
European Journal of Immunology  
e-mail: ejied@wiley.com  
www.eji-journal.eu  
 
*****************************************************  
 
Reviewer: 1  
 
Comments to the Author  
The authors have adequately addressed my previous concerns and have added new data that add to the 
mechanistic insight of the presented studies. The manuscript is greatly improved. 
  
Reviewer: 2  
 
Comments to the Author  
The authors present a wealth of new data. They have addressed many of the issues raised by the 
reviewers. However, the following questions remain unanswered: 
 1. Is the negative regulatory effect of IL-10 on cytotoxicity a cell-autonomous autoregulatory effect or 
rather an effect promoted by IL-10 secreting cells distinct from those promoting cytotoxicity? 
 2. How does IL-10 affect the cytotoxicity? It does not seem to influence FasL expression. 
 3. How exactly does IL-2 enhance cytotoxicity?  
Note, that IL-2 is introduced relatively late in the manuscript. In views of the open questions and the length 
of teh manuscript it might be better to omit the data on IL-2 to prevent dilution of the message on Il-10. 
 For gating strategies the authors should not refer to previous publications. 
 
 
Second revision – authors’ response – 1 December 2014 
 
Thank you for allowing us to make minor revisions to the above manuscript.  We have made all the 
suggested changes by the Editorial staff.  In addition we have made the following revisions: 
1. All the figure legends have been revised to follow the Journal’s standards. 
2. We have deleted the data regarding IL-2R expression and enhancing effects of IL-2 administration 
as suggested by Reviewer 2.  This has resulted in changing the title, shortening the Results section, and 
eliminating one of the Figures. 
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3. We have responded to Reviewer 2’s queries by addressing them in the Discussion.  All changes 
in the manuscript have been highlighted in red. 
4. As requested by Reviewer 2, we have described the gating strategies used for the flow analysis in 
the Legends of the appropriate figures, and have not referred to previous publications. 
5. We have revised the References to conform to the Journal’s standards. 
We look forward to having this manuscript published by the Journal. 
 
 
Third Editorial Decision – 11 December 2014  
 
Dear Prof. Li,  
 
It is a pleasure to provisionally accept your manuscript entitled "Antitumor effector B-cells directly kill 
tumor cells via the Fas/FasL pathway and are regulated by IL-10" for publication in the European Journal 
of Immunology. For final acceptance, please follow the instructions below and return the requested items 
as soon as possible as we cannot process your manuscript further until all items listed below are dealt 
with. 
  
Please note that EJI articles are now published online a few days after final acceptance (see Accepted 
Articles: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141/accepted). The files used for the 
Accepted Articles are the final files and information supplied by you in Manuscript Central. You should 
therefore check that all the information (including author names) is correct as changes will NOT be 
permitted until the proofs stage. 
  
We look forward to hearing from you and thank you for submitting your manuscript to the European 
Journal of Immunology. 
  
Yours sincerely,  
Karen Chu  
 
on behalf of Prof. David Gray  
 
Dr. Karen Chu  
Editorial Office  
European Journal of Immunology  
e-mail: ejied@wiley.com  
www.eji-journal.eu 
